Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pharma Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111328332A details a novel synthetic route for cholic and deoxycholic acid from plant-derived DHEA, ensuring high purity and eliminating animal-derived impurities for reliable supply chains.
Novel environmental-friendly amikacin synthesis reduces steps and waste. Ideal for reliable API supplier partnerships ensuring high purity and cost efficiency.
Patent CN1296472A reveals a method suppressing by-products for high-yield diamine synthesis, offering cost-effective supply chain solutions.
Advanced crystallization technology ensures >99.85% purity for Ritonavir intermediates, offering significant cost reduction in pharma intermediate manufacturing and supply chain reliability.
Patent CN106966947B reveals a high-purity Vildagliptin route. Discover cost reduction in API manufacturing and reliable pharmaceutical intermediates supplier capabilities.
Patent CN102249976B discloses a scalable route to (-)-clausenamide using fructose-derived catalysts, offering high purity and cost-effective manufacturing for pharmaceutical intermediates.
Novel method for 5-acyl-2-imine thiazolines via carbodiimide and acyl chloride. High purity, scalable process for agrochemical and pharmaceutical applications.
Discover the environmentally friendly synthesis of chiral 2,3-alkenols using lipase catalysis. A breakthrough in pharmaceutical intermediate manufacturing offering high purity and cost efficiency.
Patent CN1240646C details a novel enzymatic process for high-purity (-)-menthol. Discover cost-effective synthetic routes and supply chain advantages for global procurement.
Novel chiral auxiliary method for Lamivudine production offering superior stereocontrol and simplified purification for reliable pharmaceutical intermediate supply chains.
Patent CN116640737A reveals novel BsER mutants for asymmetric reduction. Enables cost reduction in API manufacturing with high stereoselectivity and supply reliability.
Patent CN1265092A details a continuous aqueous process for L-carnitine using (S)-3-activated hydroxybutyrolactone, offering high purity and cost efficiency.
Patent CN116640737A reveals novel BsER mutants for chiral ketone reduction. Enables high-purity pharmaceutical intermediates with reduced manufacturing costs and enhanced supply reliability.
Patent CN113024454A reveals a novel synthesis for brigatinib intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN1761742A reveals recombinant lactonase technology for efficient D-pantolactone synthesis, offering cost reduction and supply stability for vitamin B5 manufacturers.
Advanced chiral resolution technology for 2-heterocyclic dihydropyrimidines using binaphthol phosphate. Delivers >99% optical purity for scalable hepatitis B drug manufacturing.
Novel gold-catalyzed route ensures safe scalable production of high-purity nucleoside analogs with significant cost and supply chain advantages for pharmaceutical partners.
Patent CN108118035B reveals high-concentration enzymatic route reducing costs and improving purity for global supply chains.
Novel silver-catalyzed cyclization for trifluoromethyl cyclopentenes. Efficient route for pharma intermediates with mild conditions and high yields.
Novel enzymatic route for S-indoline-2-carboxylic acid ensures >99% ee purity and simplified processing for reliable pharmaceutical intermediate supply chains.